SPOTLIGHT: Gardasil wins priority review


The FDA is giving a priority review to Merck's request to expand the use of Gardasil to protect against cervical cancer in women up to the age of 45. The vaccine is currently approved for girls aged 9 to 26. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.